Cidara is pursuing a balanced infectious disease-focused development strategy intended to transform standards of care and save lives.

Pipeline

Rezafungin

  IND-Enabling
Phase 1
Phase 2
Phase 3

Rezafungin Treatment (IV)

Candidemia and Invasive Candidiasis

Phase 3 Initiated

80%

Rezafungin Prophylaxis (IV)

Candida, PCP and Aspergillus in alloBMT

Phase 3 Planned Start Q1 2019

78%

Rezafungin Subcutaneous

Fungal Infections

Phase 1 Planned Start 1H 2019

26%

Cloudbreak

Research
IND-Enabling
Phase 1
Phase 2

Antibody Drug Conjugate (ADC)

Gram (-) Bacteria

Research

26%

Antibody Drug Conjugate (ADC)

Viral Infections – Influenza

Research

26%

Plans and timelines for clinical studies are subject to regulatory interactions.

GET IMPORTANT NEWS AND UPDATES BY EMAIL